Johan De Meester1, Dirk De Bacquer2, Maarten Naesens3,4, Bjorn Meijers3,4, Marie M Couttenye5, An S De Vriese6,7. 1. Division of Nephrology, Dialysis and Hypertension, AZ Nikolaas Hospital, Sint-Niklaas, Belgium. 2. Department of Public Health and Primary Care, Ghent University, Ghent, Belgium. 3. Division of Nephrology and Kidney Transplantation, UZ Leuven, Leuven, Belgium. 4. Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium. 5. Department of Nephrology, Antwerp University Hospital and Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium. 6. Division of Nephrology and Infectious Diseases, AZ Sint-Jan Brugge, Brugge, Belgium an.devriese@azsintjan.be. 7. Department of Internal Medicine, Ghent University, Ghent, Belgium.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection disproportionally affects frail, elderly patients and those with multiple chronic comorbidities. Whether patients on RRT have an additional risk because of their specific exposure and complex immune dysregulation is controversial. METHODS: To describe the incidence, characteristics, and outcomes of SARS-CoV-2 infection, we conducted a prospective, multicenter, region-wide registry study in adult patients on RRT versus the general population from March 2 to May 25, 2020. This study comprised all patients undergoing RRT in the Flanders region of Belgium, a country that has been severely affected by coronavirus disease 2019 (COVID-19). RESULTS: At the end of the epidemic wave, crude and age-standardized cumulative incidence rates of SARS-CoV-2 infection were 5.3% versus 2.5%, respectively, among 4297 patients on hemodialysis, and 1.4% versus 1.6%, respectively, among 3293 patients with kidney transplants (compared with 0.6% in the general population). Crude and age-standardized cumulative mortality rates were 29.6% versus 19.9%, respectively, among patients on hemodialysis, and 14.0% versus 23.0%, respectively, among patients with transplants (compared with 15.3% in the general population). We found no excess mortality in the hemodialysis population when compared with mean mortality rates during the same 12-week period in 2015-2019 because COVID-19 mortality was balanced by lower than expected mortality among uninfected patients. Only 0.18% of the kidney transplant population died of SARS-CoV-2 infection. CONCLUSIONS: Mortality associated with SARS-CoV-2 infection is high in patients on RRT. Nevertheless, the epidemic's overall effect on the RRT population remained remarkably limited in Flanders. Calculation of excess mortality and age standardization provide a more reliable picture of the mortality burden of COVID-19 among patients on RRT.
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection disproportionally affects frail, elderly patients and those with multiple chronic comorbidities. Whether patients on RRT have an additional risk because of their specific exposure and complex immune dysregulation is controversial. METHODS: To describe the incidence, characteristics, and outcomes of SARS-CoV-2 infection, we conducted a prospective, multicenter, region-wide registry study in adult patients on RRT versus the general population from March 2 to May 25, 2020. This study comprised all patients undergoing RRT in the Flanders region of Belgium, a country that has been severely affected by coronavirus disease 2019 (COVID-19). RESULTS: At the end of the epidemic wave, crude and age-standardized cumulative incidence rates of SARS-CoV-2 infection were 5.3% versus 2.5%, respectively, among 4297 patients on hemodialysis, and 1.4% versus 1.6%, respectively, among 3293 patients with kidney transplants (compared with 0.6% in the general population). Crude and age-standardized cumulative mortality rates were 29.6% versus 19.9%, respectively, among patients on hemodialysis, and 14.0% versus 23.0%, respectively, among patients with transplants (compared with 15.3% in the general population). We found no excess mortality in the hemodialysis population when compared with mean mortality rates during the same 12-week period in 2015-2019 because COVID-19 mortality was balanced by lower than expected mortality among uninfected patients. Only 0.18% of the kidney transplant population died of SARS-CoV-2 infection. CONCLUSIONS: Mortality associated with SARS-CoV-2 infection is high in patients on RRT. Nevertheless, the epidemic's overall effect on the RRT population remained remarkably limited in Flanders. Calculation of excess mortality and age standardization provide a more reliable picture of the mortality burden of COVID-19 among patients on RRT.
Authors: Mario Fernández-Ruiz; Amado Andrés; Carmelo Loinaz; Juan F Delgado; Francisco López-Medrano; Rafael San Juan; Esther González; Natalia Polanco; María D Folgueira; Antonio Lalueza; Carlos Lumbreras; José M Aguado Journal: Am J Transplant Date: 2020-05-10 Impact factor: 8.086
Authors: Carolin Edler; Ann Sophie Schröder; Martin Aepfelbacher; Antonia Fitzek; Axel Heinemann; Fabian Heinrich; Anke Klein; Felicia Langenwalder; Marc Lütgehetmann; Kira Meißner; Klaus Püschel; Julia Schädler; Stefan Steurer; Herbert Mushumba; Jan-Peter Sperhake Journal: Int J Legal Med Date: 2020-06-04 Impact factor: 2.686
Authors: Enver Akalin; Yorg Azzi; Rachel Bartash; Harish Seethamraju; Michael Parides; Vagish Hemmige; Michael Ross; Stefanie Forest; Yitz D Goldstein; Maria Ajaimy; Luz Liriano-Ward; Cindy Pynadath; Pablo Loarte-Campos; Purna B Nandigam; Jay Graham; Marie Le; Juan Rocca; Milan Kinkhabwala Journal: N Engl J Med Date: 2020-04-24 Impact factor: 91.245
Authors: Paul V Ritschl; Nora Nevermann; Leke Wiering; Helen H Wu; Philipp Moroder; Andreas Brandl; Karl Hillebrandt; Frank Tacke; Frank Friedersdorff; Thorsten Schlomm; Wenzel Schöning; Robert Öllinger; Moritz Schmelzle; Johann Pratschke Journal: Am J Transplant Date: 2020-05-10 Impact factor: 9.369
Authors: Daniel F Gudbjartsson; Agnar Helgason; Hakon Jonsson; Olafur T Magnusson; Pall Melsted; Gudmundur L Norddahl; Jona Saemundsdottir; Asgeir Sigurdsson; Patrick Sulem; Arna B Agustsdottir; Berglind Eiriksdottir; Run Fridriksdottir; Elisabet E Gardarsdottir; Gudmundur Georgsson; Olafia S Gretarsdottir; Kjartan R Gudmundsson; Thora R Gunnarsdottir; Arnaldur Gylfason; Hilma Holm; Brynjar O Jensson; Aslaug Jonasdottir; Frosti Jonsson; Kamilla S Josefsdottir; Thordur Kristjansson; Droplaug N Magnusdottir; Louise le Roux; Gudrun Sigmundsdottir; Gardar Sveinbjornsson; Kristin E Sveinsdottir; Maney Sveinsdottir; Emil A Thorarensen; Bjarni Thorbjornsson; Arthur Löve; Gisli Masson; Ingileif Jonsdottir; Alma D Möller; Thorolfur Gudnason; Karl G Kristinsson; Unnur Thorsteinsdottir; Kari Stefansson Journal: N Engl J Med Date: 2020-04-14 Impact factor: 91.245
Authors: Chiara Cantarelli; Andrea Angeletti; Laura Perin; Luis Sanchez Russo; Gianmarco Sabiu; Manuel Alfredo Podestà; Paolo Cravedi Journal: Clin Kidney J Date: 2022-07-27
Authors: Jens Van Praet; Marijke Reynders; Dirk De Bacquer; Liesbeth Viaene; Melanie K Schoutteten; Rogier Caluwé; Peter Doubel; Line Heylen; Annelies V De Bel; Bruno Van Vlem; Deborah Steensels; An S De Vriese Journal: J Am Soc Nephrol Date: 2021-09-29 Impact factor: 10.121
Authors: Sri Lekha Tummalapalli; Jeffrey Silberzweig; Daniel Cukor; Jonathan T Lin; Tarek Barbar; Yao Liu; Kwan Kim; Thomas S Parker; Daniel M Levine; Said A Ibrahim Journal: J Am Soc Nephrol Date: 2021-06-03 Impact factor: 14.978
Authors: Raphaël Duivenvoorden; Priya Vart; Marlies Noordzij; Augusto C Soares Dos Santos; Alex B Zulkarnaev; Casper F M Franssen; Dirk Kuypers; Erol Demir; Hormat Rahimzadeh; Julia Kerschbaum; Kitty J Jager; Kultigin Turkmen; Marc H Hemmelder; Marcel Schouten; María Luisa Rodríguez-Ferrero; Marta Crespo; Ron T Gansevoort; Luuk B Hilbrands Journal: Transplantation Date: 2022-04-26 Impact factor: 5.385
Authors: Kurtis A Pivert; Suzanne M Boyle; Susan M Halbach; Lili Chan; Hitesh H Shah; Joshua S Waitzman; Ali Mehdi; Sayna Norouzi; Stephen M Sozio Journal: J Am Soc Nephrol Date: 2021-03-03 Impact factor: 10.121